Open AccessEndothelial dysfunction in patients with lymphoproliferative disorders and its changes in the course of polychemotherapy
Author(s) -
И. Л. Давыдкин,
Т. П. Кузьмина,
К. В. Наумова,
Rais Kettdusovich Khayretdinov,
О. Е. Данилова,
Tatyana Yu. Stepanova,
Alexey M. Osadchuk,
Elizaveta V. Mordvinova
Publication year - 2020
Publication title -
russian open medical journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.137
H-Index - 8
ISSN - 2304-3415
DOI - 10.15275/rusomj.2020.0309
Subject(s) - subclinical infection , medicine , endothelial dysfunction , lymphoproliferative disorders , chemotherapy , disease , oncology , immunology , lymphoma
The article is dedicated to contemporary views on the change of endothelial function in the patients with lymphoproliferative disorders prior to, and in the process of, chemotherapeutic treatment. Considering that possibilities of standard examination do not always help identifying subclinical endothelial dysfunction, it is necessary to use specific methods, in particular, to determine the levels of endothelin-1 and vascular endothelial growth factor to monitor endothelial function. The objective of this review is to identify problems and prospects for recognizing early subclinical changes of endothelial function in the patients with lymphoproliferative disorders before and after chemotherapy. Assessing presence and severity of endothelial dysfunction may be useful for determining subclinical stages of cardiovascular damage, stratifying the risk of the patients with confirmed cardiovascular disease, and reducing the likelihood of cardio- and endotheliotoxic effects in patients long after chemotherapy. That is why early detection and immediate therapy of cardiovascular toxicity is currently the most important task in the patients with lymphoproliferative disorders, receiving chemotherapy.